Executive Board
Andreas Grassauer is Chairman of the Executive Board and Chief Executive Officer. He co-founded Marinomed in 2006 and since then has been CEO of the Company. Prior to founding Marinomed, he built up several other companies and was involved in raising more than EUR 30 million from private and public sources. In the last fifteen years, he executed a series of deals for Marinomed. Andreas Grassauer holds a doctoral degree (PhD) in virology from the Institute of Applied Microbiology at the University of Natural Resources and Applied Life Sciences, Vienna, Austria.
Eva Prieschl-Grassauer is Chief Scientific Officer. She co-founded Marinomed in 2006 and has been CSO of the Company since 2007. Eva Prieschl-Grassauer has more than 30 years of experience in pharmaceutical drug development. Prior to her appointment at Marinomed, she was head of the allergy program of Novartis in Vienna, Austria. In this position, she discovered the mechanism of action of FTY720 (fingolimod), Novartis’ immunomodulatory drug against multiple sclerosis. Eva Prieschl-Grassauer has published more than 50 articles in prestigious peer-reviewed journals in the fields of immunology, molecular biology and medicinal chemistry. She holds a doctoral degree (PhD) in immunology from the University of Vienna, Austria. In 2022, she was awarded the Golden Decoration of Merit of the Republic of Austria for her excellent scientific work and its translation into commercial success.
Authorized Signatory
Mrs. Ram has extensive financial experience. In the past 10 years, she has held several C-Level positions in various companies in Germany and Austria. Until recently, she served as CFO for Wienerberger Piping Solutions, a former business unit of the stock-listed Wienerberger AG.
Supervisory Board
Simon Nebel is founder and Managing Partner of Viopas Venture Consulting GmbH. He is also a venture partner of Aravis, a private equity firm for which he has participated in financing a number of life science companies and M&A transactions of the Aravis portfolio. Moreover, Simon Nebel is currently a Supervisory Board member of Quadia SA, Kivu BioScience B.V., RhyVest AG, Hanaku AG and Bio-sensing Solutions SL. Simon Nebel holds a PhD in biophysics from the Biocentre of the University of Basel, Switzerland, and an MBA with distinction from the London Business School. Simon Nebel is a member of the Company’s Supervisory Board and has been its Chairman since 2017. He was previously Chairman of the Company’s Advisory Board (from 2008 onwards).
Elisabeth Lackner is CEO of CRS Clinical Research Services and well-networked pharmaceutical and biotechnology executive with more than 20 years of experience combining growth, business strategy & innovation, marketing, business development and international expansion, regulatory and operations in life science with full P&L responsibility, thereof 10+ years as CEO. Elisabeth Lackner holds a PhD in pharmaceutical sciences from the University of Vienna, is a respected consultant and speaker in the pharmaceutical and biotech industry and has been a member of the Supervisory Board since 2022.
Karl Mahler holds a doctorate in economics and has extensive experience in various management positions in pharmaceutical and life science companies in the field of strategic and investment planning. He was also Head of Investor Relations at Hoffmann La Roche for 20 years, where he was involved in major transactions and financing as well as M&A activities. Since his retirement, Karl Mahler has been working as a senior advisor for McKinsey.
Scientific Advisory Board
Professor of Ophthalmology & Director of Cornea Research at the Moran Eye Institute at the University of Utah, ophthalmologist at Pacific Clear Vision Institute and co-founder & President of iVeena. Experienced in cornea transplants, cataract extraction, keratoprosthesis (artificial cornea), LASIK, and other complex procedures of the cornea and anterior segment of the eye. Globally recognized as the world's youngest person to graduate from medical school, at age 17.
Talin Barisani-Asenbauer has studied Medicine at the University of Vienna, Austria. She started her career in 1987 at the Department of Ophthalmology as scientific coworker and from 1990 to 1997 she completed her residency in ophthalmology with special emphasis on ocular immunology and infectiology. In 1997 she became the director of the Uveitis unit and the working group “ocular immunology & infectiology”. In 2001 she was awarded the habilitation degree by the University of Vienna.
Director of Research at the Wellington Asthma Research Group, University of Otago, New Zealand. The Group's research program covers clinical, biomedical, and public health aspects of allergy, asthma, and respiratory research, including studies to understand the causes and investigate novel treatments.
Founder and Director of the Common Cold Centre at Cardiff University, Wales UK 1988-2017. Expertise in the physiology, pharmacology, pathophysiology, and therapeutics of the upper airways for diseases such as common cold, influenza and allergy. Expertise in the mechanism and treatment of upper airway disease symptoms and conduction of clinical trials.